Published in Wiley Interdiscip Rev Nanomed Nanobiotechnol on March 25, 2016
Near-IR-induced dissociation of thermally-sensitive star polymers. Chem Sci (2016) 0.75
Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma. PLoS One (2017) 0.75
Drug delivery systems: entering the mainstream. Science (2004) 9.27
Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol (2008) 8.23
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A (2008) 7.06
Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J (2004) 6.90
Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol (2007) 6.85
Design and development of polymers for gene delivery. Nat Rev Drug Discov (2005) 6.79
Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A (2006) 6.62
Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther (2007) 5.79
Immunological properties of engineered nanomaterials. Nat Nanotechnol (2007) 5.59
The challenge of new drug discovery for tuberculosis. Nature (2011) 4.23
Physical approaches to biomaterial design. Nat Mater (2009) 4.01
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A (2007) 3.94
The emerging nanomedicine landscape. Nat Biotechnol (2006) 3.60
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev (2008) 3.41
Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol (2013) 3.39
Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) (2011) 3.33
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev (2009) 3.17
Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release (2009) 3.08
Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol (2010) 2.85
Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release (2007) 2.74
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther (2008) 2.69
Micro- and macrorheology of mucus. Adv Drug Deliv Rev (2009) 2.54
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol (2013) 2.54
Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov (2007) 2.42
Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl (2008) 2.38
Role of particle size in phagocytosis of polymeric microspheres. Pharm Res (2008) 2.23
Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev (2012) 2.11
Polymer particle shape independently influences binding and internalization by macrophages. J Control Release (2010) 2.05
Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov (2010) 2.04
Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem (2003) 2.01
Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small (2011) 2.00
Shape induced inhibition of phagocytosis of polymer particles. Pharm Res (2008) 1.91
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A (2009) 1.86
Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol (2007) 1.86
Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev (2008) 1.77
Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm (2000) 1.73
Nanoparticles for drug delivery to the lungs. Trends Biotechnol (2007) 1.73
Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol (2008) 1.72
Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther (2003) 1.61
Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. Biomaterials (2007) 1.59
Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm (2009) 1.59
Nanoparticles of compacted DNA transfect postmitotic cells. J Biol Chem (2003) 1.58
Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm (2002) 1.55
The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials (2009) 1.54
Advanced drug delivery systems that target the vascular endothelium. Mol Interv (2006) 1.54
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother (2003) 1.49
Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst (2002) 1.45
Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des (2010) 1.45
Particle engineering for pulmonary drug delivery. Pharm Res (2007) 1.41
The rise and rise of drug delivery. Nat Rev Drug Discov (2005) 1.39
Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother (2008) 1.37
Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release (2006) 1.36
Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med (2000) 1.35
Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials (2009) 1.35
Silver against Pseudomonas aeruginosa biofilms. APMIS (2007) 1.33
The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc (2004) 1.32
A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov (2015) 1.31
Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol Appl Pharmacol (2003) 1.30
Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm (2010) 1.29
New polymeric carriers for controlled drug delivery following inhalation or injection. Biomaterials (2002) 1.27
Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm (2013) 1.27
Macrophages recognize size and shape of their targets. PLoS One (2010) 1.26
Nanomedicine for respiratory diseases. Eur J Pharmacol (2006) 1.23
Nanoparticle formulations in pulmonary drug delivery. Med Res Rev (2009) 1.23
Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev (2008) 1.22
Pulmonary collectins enhance phagocytosis of Mycobacterium avium through increased activity of mannose receptor. J Immunol (2004) 1.21
The antimicrobial efficacy of sustained release silver-carbene complex-loaded L-tyrosine polyphosphate nanoparticles: characterization, in vitro and in vivo studies. Biomaterials (2009) 1.20
Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol (2006) 1.19
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) (2003) 1.18
Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. J Control Release (2010) 1.18
Nanoparticles in the lung. Nat Biotechnol (2010) 1.14
Immortalization of human alveolar epithelial cells to investigate nanoparticle uptake. Am J Respir Cell Mol Biol (2008) 1.13
Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. Mol Pharm (2009) 1.12
Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev (2010) 1.11
Cellular uptake and intracellular pathways of PLL-g-PEG-DNA nanoparticles. Bioconjug Chem (2008) 1.11
Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials (2013) 1.11
Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 1.10
Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond) (2010) 1.10
Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anticancer Drugs (2010) 1.08
Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano (2012) 1.08
Strategies Toward Well-Defined Polymer Nanoparticles Inspired by Nature: Chemistry versus Versatility. J Polym Sci A Polym Chem (2012) 1.07
Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev (2013) 1.05
Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm Pharmacol Ther (2006) 1.04
Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation. J Control Release (2011) 1.03
Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J Control Release (2014) 1.03
Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano (2013) 1.02
Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. J Control Release (2004) 1.02
Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond) (2011) 1.01
Characterization of endocytosis and exocytosis of cationic nanoparticles in airway epithelium cells. Nanotechnology (2010) 1.01
Swellable microparticles as carriers for sustained pulmonary drug delivery. J Pharm Sci (2010) 1.00
Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol (2010) 0.99
Mucolytics in cystic fibrosis. Paediatr Respir Rev (2007) 0.99
Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother (2004) 0.99
N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol Ther (2011) 0.98
Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. PLoS One (2013) 0.98
Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm (2009) 0.98
Smart hybrid materials by conjugation of responsive polymers to biomacromolecules. Nat Mater (2014) 0.97